Overview of Stem Cell Transplantation for Lymphoma

Part of the Cancer Drug Discovery and Development book series (CDD&D)


Although the cure rate for many types of lymphoma has increased with the use of chemotherapy and monoclonal antibody treatment, approximately 50% of lymphoma patients will relapse and be candidates for either autologous or allogeneic transplantation. In this section, we examine the results of clinical transplantation in low-grade, intermediate, and high-grade lymphoma. We also review the results of older patients with lymphoma. Finally, we discuss the emerging and exciting results with the use of umbilical cord blood for patients without matched related or unrelated donors.


Umbilical Cord Blood Mantle Cell Lymphoma Autologous Stem Cell Transplant Primary Central Nervous System Lymphoma Unrelated Donor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rohatiner AZS, Nadler L, Davies AJ et al (2007) Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 25:1–6CrossRefGoogle Scholar
  2. 2.
    Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667–2674PubMedCrossRefGoogle Scholar
  3. 3.
    Kuruvilla J, Pond G, Tsang R et al (2008) Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant 14:775–782PubMedCrossRefGoogle Scholar
  4. 4.
    Khouri IF, Saliba RM, Erwin WD et al (2012) Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12 year results. Blood 119:6373–6378PubMedCrossRefGoogle Scholar
  5. 5.
    Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545PubMedCrossRefGoogle Scholar
  6. 6.
    Bacher U, Klyuchnikov E, Le-Rademacher J et al (2012) Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity. Blood (epub ahead of print)Google Scholar
  7. 7.
    Gisselbrecht C, Schmitz N, Mounier N et al (2012) Rituximab maintenance therapy after autologous stem cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol (epub ahead of print)Google Scholar
  8. 8.
    Thomson KJ, Morris EC, Cook G et al (2008) Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 27:426–432PubMedCrossRefGoogle Scholar
  9. 9.
    O’Meara A, Halter J, Heim D et al (2012) Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/Fludarabine/TBI. Bio Blood Marrow Transplant (e pub ahead of print)Google Scholar
  10. 10.
    Levine JH, Harris RE, Loberiza FR et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482PubMedCrossRefGoogle Scholar
  11. 11.
    Rossi HA, Becker PS, Emmons RVB et al (2003) High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 31:441–446PubMedCrossRefGoogle Scholar
  12. 12.
    Velders GA, Kluin-Nelemans JC, De Boer CJ et al (1996) Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14:1269–1274PubMedGoogle Scholar
  13. 13.
    Dreyling A, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105:2677–2684PubMedCrossRefGoogle Scholar
  14. 14.
    Geisler CH, Kolstad A, Laurell A et al (2008) Long-term progression free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in-vivo purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687–2693PubMedCrossRefGoogle Scholar
  15. 15.
    Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144–4152PubMedCrossRefGoogle Scholar
  16. 16.
    Vose JM (2012) Autotransplantation for mantle cell lymphoma. Cancer J 18:427–431PubMedCrossRefGoogle Scholar
  17. 17.
    Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European blood and marrow transplant and autologous blood and marrow transplant registries. Br J Haematol 120:793–800PubMedCrossRefGoogle Scholar
  18. 18.
    Khouri IF, Champlin RE (2012) Nonmyeloablative allogeneic stem cell transplantation for non-Hodgkins lymphoma. Cancer J 18:457–462PubMedCrossRefGoogle Scholar
  19. 19.
    Yusuf RZ, Dey B, Yeap BY et al (2009) Autologous stem cell transplantation with a dose reduced busulfan and cyclophosphamide regimen in older patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant 43:37–42PubMedCrossRefGoogle Scholar
  20. 20.
    Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643–5645PubMedCrossRefGoogle Scholar
  21. 21.
    Ferreri AJM, Crocchiolo R, Assanelli A et al (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042–2047PubMedCrossRefGoogle Scholar
  22. 22.
    Ballen KK, King RJ, Chitphakdithai P et al (2008) The National Marrow Donor Program experience: the first 20 years of unrelated donor stem cell transplantation. Biol Blood Marrow Transplant 14:2–7PubMedCrossRefGoogle Scholar
  23. 23.
    Kurtzberg J, Laughlin M, Graham ML et al (1996) Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 335:157–166PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang MJ, Davies SM, Camitta BM et al (2012) Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 18:1204–1210PubMedCrossRefGoogle Scholar
  25. 25.
    Cutler C, Stevenson K, Kim HT et al (2011) Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus based GVHD prophylaxis. Bone Marrow Transplant 46:273–277CrossRefGoogle Scholar
  26. 26.
    Brunstein CG, Fuchs EJ, Carter SL et al (2011) Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated donor umbilical cord blood grafts. Blood 118:282–288PubMedCrossRefGoogle Scholar
  27. 27.
    Chen YB, Aldridge J, Kim HT et al (2012) Reduced intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 18:805–812PubMedCrossRefGoogle Scholar
  28. 28.
    Rodrigues CA, Sanz G, Brunstein CG et al (2008) Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 27:256–263PubMedCrossRefGoogle Scholar
  29. 29.
    Brunstein CG, Gutman JA, Weisdorf DJ et al (2010) Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693–4699PubMedCrossRefGoogle Scholar
  30. 30.
    Fernandez HF, Escalon MP, Pereira D et al (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 40:505–513PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of Hematology/OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations